Shares of Acadia Pharmaceuticals (NASDAQ: ACAD) rose by as much as 19.2% in premarket trading Tuesday morning. The biotech's stock is taking flight today in response to a positive clinical readout for its experimental Rett syndrome drug known as trofinetide. Rett syndrome is a rare genetic disorder characterized by the progressive degeneration of motor and speech skills.
Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting